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Abstract
The objective of the study was to identify immune cell populations, in addition to Foxp3+ T-regulatory cells, that participate
in the mechanisms of action of tolerogenic dendritic cells shown to prevent and reverse type 1 diabetes in the Non-Obese
Diabetic (NOD) mouse strain. Co-culture experiments using tolerogenic dendritic cells and B-cells from NOD as well as
transgenic interleukin-10 promoter-reporter mice along with transfer of tolerogenic dendritic cells and CD19+ B-cells into
NOD and transgenic mice, showed that these dendritic cells increased the frequency and numbers of interleukin-10-
expressing B-cells in vitro and in vivo. The expansion of these cells was a consequence of both the proliferation of pre-
existing interleukin-10-expressing B-lymphocytes and the conversion of CD19+ B-lymphcytes into interleukin-10-expressing
cells. The tolerogenic dendritic cells did not affect the suppressive activity of these B-cells. Furthermore, we discovered that
the suppressive murine B-lymphocytes expressed receptors for retinoic acid which is produced by the tolerogenic dendritic
cells. These data assist in identifying the nature of the B-cell population increased in response to the tolerogenic dendritic
cells in a clinical trial and also validate very recent findings demonstrating a mechanistic link between human tolerogenic
dendritic cells and immunosuppressive regulatory B-cells.
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Introduction
Re-establishment of peripheral tolerance has long been sought
as a method to effectively treat type 1 diabetes mellitus (T1D)
especially new-onset disease, since functional beta cell mass can
persist for months to years after clinical diagnosis. T1D is an
autoimmune disease due to the loss of insulin production
consequent to a chronic inflammation-driven impairment and
eventual eradication of a critical mass of pancreatic beta cells
[1,2,3]. Studies conducted in non-obese diabetic (NOD) mice, a
strain that spontaneously develops diabetes of an autoimmune
nature, have highlighted the critical role of the adaptive immune
response in the pathogenesis of the disease [4,5].
It is now clear that the targeting of insulin by the immune
system, the underlying immune hallmark of T1D etiopathogenesis,
is a result of central (thymic) and peripheral tolerance failure [6].
Central failure is a consequence of impaired expression and
presentation of proinsulin to nascent thymocytes by medullary
thymic epithelial cells [7,8]. Peripheral failure is a chronic process
characterised by pathologic changes to regulatory immune cell
populations in the secondary lymphoid organs [9,10,11,12,13].
Rebalancing the regulatory:effector immune cell numbers in the
periphery by taking advantage of homeostatic expansion of
populations like T-cells and B-cells secondary to their deletion
using antibodies, for example, has resulted in attenuation of a
variety of experimental autoimmunity in mice and rats, including
remission of T1D [14,15,16]. The preservation of residual beta cell
mass and, in some instances, the temporary withdrawal of insulin
treatment in new onset T1D subjects, believed to be due to the
rebalancing of the Foxp3+ T-cell:effector T-cell population
following the depletion of T-cells using a CD3-targeting antibody,
is one of the modern examples where restoration of peripheral
tolerance was successfully, even though transiently, achieved
[17,18,19].
In addition to Foxp3+ regulatory T-cells, DC are key regulators
of peripheral tolerance making them promising therapeutic
vehicles to treat autoimmunity including T1D. Key general
features of DCs that activate and maintain immunosuppressive
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states include: low antigen-presentation capacity (low levels of class
I and class II MHC expression on the cell surface), low-to-absent
co-stimulation ability, poor to absent allostimulatory ability to
induce T-cell proliferation in allogeneic mixed leukocyte culture or
in antigen-specific recall responses, production of TH2-type
cytokines and retinoic acid [20,21]. We have shown that
administration of DC treated ex vivo with short double-stranded
NF-kappaB oligonucleotide decoys [22] and antisense oligonucle-
otides targeting CD40, CD80 and CD86 can prevent T1D in the
non-obese diabetic (NOD) mouse strain [23] and can prolong
allograft survival [24]. Administration of these immunosuppressive
DC promotes production of cytokines that impair T-cell activation
and is associated with increased numbers and enhanced function
of Foxp3+ T regulatory (Treg) cells [reviewed in [25,26]]. Indeed,
the success of suppressive DC-based therapies to upregulate
Foxp3+ Tregs are particularly striking in diabetic mouse models
[27,28]. In addition to the reproducible effects of DC on Treg
upregulation, emerging data indicate that other immunoregulato-
ry cells, including NKT [29] and B-lymphocytes [30] are DC-
senstitive in their role of maintaining/promoting tolerance.
The involvement of B-lymphocytes in the etiopathogenesis of
T1D was first uncovered in the NOD mouse strain, where mice
deficient in B-lymphocytes as a consequence of IgM mutation, or
treatment with anti-IgM antibodies exhibited significant protec-
tion from the disease [31,32]. Most studies suggested that the
pathogenic role of B-lymphocytes lies largely in their ability to act
as antigen-presenting cells [33,34,35,36,37,38], producers of
autoreactive antibodies [39,40] and modulators of the type of T-
cells that enter and are active within the pancreatic and islet
environment [41]. Most importantly, B-lymphocyte depletion, by
anti-CD20, anti-CD45RB, and anti-CD22 antibodies, resulted in
the sustained and stable prevention and, in some instances, the
reversal of T1D in NOD mice [42,43,44,45,46,47] as well as
facilitation of islet allograft survival in NOD mice [44]. Indeed,
efficacy of the anti-CD20 antibody treatment in NOD mice
underlay the Rituximab clinical trial in new-onset human patients
[48,49,50]. These seemingly disparate observations were recently
reconciled with the identification of one or more B-lymphocyte
populations that are inherently immunosuppressive, whose
frequency and, possibly activity, may change over time and
during perturbations in peripheral tolerance [30,51].
Immunosuppressive B-cells, widely referred to as B-regulatory
cells (Bregs) in mice exist in the CD1dHIGH CD5+ IL-10-
producing population. These cells can suppress experimental
colitis, arthritis and lupus [52]. Adoptive transfer of LPS-
stimulated B cells prevented T1D development in NOD mice
[53], while CD40 antibody-stimulated B cells prevented arthritis
[54]. In humans, in addition to the IL-10-producing CD1d+
CD5+ B-cells [termed ‘‘B10 Bregs’’; [52,55]], CD19+ CD24HIGH
CD27+ CD38HIGH B-cells are also suppressive, relying partly on
IL-10 [56].
We have established a protocol to generate stably-immunosup-
pressive, tolerogenic DC ex vivo from peripheral blood mononu-
clear cells (PBMC) [57]. These cells are products of DC
progenitors generated in the presence of antisense DNA targeting
the primary transcripts of CD40, CD80 and CD86. Administra-
tion into established adult T1D subjects resulted in an increase in
the frequency of a B-cell population that suppressed proliferation
of syngeneic T-cells in response to allostimulation in vitro [57]. Of
note, these B-cells did not rely on IL-10 for suppressive ability.
More recently, we confirmed that these suppressive B-cells were
essentially-identical in phenotype to one population of human
Bregs [56,58,59,60] and that co-culture with co-stimulation-
impaired DC in vitro resulted in increased proliferation in vitro
[61]. Given our observations with the human suppressive B-cell
population and its response to the co-stimulation-impaired,
tolerogenic DC, we hypothesised that murine Bregs would be
similarly impacted by exposure to the murine embodiment of these
human tolerogenic DC. To address this hypothesis, we aimed to
demonstrate a direct effect of the tolerogenic DC on increasing
Breg numbers either through expansion of existing cells (prolifer-
ation) and/or differentiation of B-cells into Bregs. Concurrently,
this study was also aimed at a first understanding of the potential
mechanisms by which the tolerogenic DC could promote Breg
expansion, with a specific focus on retinoic acid.
Herein, as we affirm the ability of co-stimulation-deficient,
tolerogenic DC to reverse new onset T1D in NOD mice, we
demonstrate that the frequency of IL-10+ B-cells increases, largely
by differentiation of CD19+ B-cells, when exposed to tolerogenic
DC in vitro and in vivo. Even though CD1d+ CD5+ IL-10+ B-cells
[51,55] comprise the majority of the suppressive population
expanded in response to the tolerogenic DC, our data suggest that
IL-10 is not a conditio sine qua non for suppression of T-cell
proliferation to allostimulation in vitro. The suppression seems to
require physical contact between B-cells and T-cells. We also
report that B10 Bregs express retinoic acid (RA) receptors.
Importantly, our tolerogenic DC express aldehyde dehydrogenase
(ALDH), the rate-limiting enzyme for retinoic acid biosynthesis,
and produce RA in vitro. Taken together, our findings point to a
novel mechanism of DC-mediated suppression of T1D, involving
the induction of suppressive B-cells, including IL-10+ Bregs. Such
suppressive B-cells could in principle be readily manipulated ex vivo
or in vivo to promote tolerance to T1D and perhaps other
autoimmune conditions as an alternative, or as an additive
approach to tolerogenic DC.
Materials and Methods
Animals
Ethics Statement on Animal Use. This study was carried
out in strict accordance with the recommendations in the Guide
for the Care of Animals of the National Institutes of Health. The
protocols were approved by the IACUC of the University of
Pittsburgh (Protocol numbers 1110982 and 1112140). All proce-
dures and euthanasia were conducted according to these approved
protocols with an aim to ameliorate and potential animal
discomfort.
Female NOD/LtJ mice were purchased from Jackson Labora-
tories (Bar Harbor, ME) and were used between the ages of 8–18
weeks or when confirmed diabetic (two consecutive readings of tail
vein blood glucose .300 mg/dL). C57BL/6 transgenic mice
expressing GFP under the control of the IL-10 promoter (IL-10
GFP ‘‘knock-in’’; IL10gfp; [62] were purchased from the Jackson
Laboratories and maintained as a colony and along with the
transgenic control strain wild-type C57BL/6 female mice (Jackson
Laboratories), they were used between the ages of 7–12 weeks. All
mice were maintained in a specific pathogen-free environment in
the Animal Facility of the Rangos Research Center in accordance
with institutional, state and federal guidelines. All animal
experiments were conducted following approved protocols by
the University of Pittsburgh IACUC.
Generation of murine bone marrow-derived DC and
administration in vivo
DC (control DC or immunosuppressive DC; cDC and iDC,
respectively) were generated in vitro from bone marrow progenitors
using previously-published methods [23,63]. cDC and iDC were
administered subcutaneously (s.c.) into the abdominal flank
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overlying the predicted anatomical location of the pancreas. DC
were routinely administered at 1–26106 cells in 150–200 micro-
liters volume sterile, endotoxin-free PBS. Mice that were
confirmed to be diabetic, were immediately given between 0.5–2
units of a Novolin:Humulin (1:1) mixture i.p. once daily until non-
fasting blood glucose fell to below 280 mg/dL. From the time of
diabetes confirmation, only mice that returned to non-fasting
glucose ,280 mg/dL within a 15–20 day window of daily insulin
administration were considered for cDC or iDC treatment. On the
first day where the glucose reading was ,280 mg/dL, insulin was
stopped and cDC or iDC were immediately administered. Mice
were given either a single injection or multiple injections (eight
injections) of cDC or iDC in PBS vehicle. In the multiple injection
recipients, cDC/iDC were administered once weekly for a period
of eight weeks. No insulin was given during the DC treatment or at
any time thereafter. Glucose monitoring continued twice weekly
for a period of 30 days, and then once weekly for at least 6 months
when normoglycemic mice were euthanized. Mice that returned to
diabetes at any time after the DC treatment were euthanized. An
additional control group of mice were treated with insulin to
normalise glucose and then insulin was withdrawn. These mice
were euthanised upon return of hyperglycemia.
Multiparameter/multicolor flow cytometry and flow
sorting
We used a FACSCalibur/FACSAria with DIVA support (BD
Biosciences) with species-specific antibodies, non-overlapping
fluorophores and appropriate isotype controls for flow-sorting
and flow cytometry. With the exception of experiments where the
ALDEFLUOR reagent was used (see further below), in all
measurements of DC populations, Fc-Block (BD Biosciences)
was used prior to antibody staining. Cells were antibody-stained
either after pre-enrichment for specific populations over magnetic
columns (e.g. CD3+ T-cells or CD19+ B220+ B-cells; MIltenyi
Biotec), or stained as freshly-isolated single cells from spleen and/
or pancreatic lymph nodes or from cultured cells in vitro. The
antibodies used for flow cytometry and/or flow sorting (all from
BD Biosciences) were - B220 (clone RA3-6B2), CD19 (clone 1D3),
CD27 (clone M-T271), CD38 (clone 90), CD38 (clone HIT2),
CD5 (clone 53-7.3), CD1d (clone 1B1), IgD (clone 11.26c.2a), IgM
(clone R6-60.2), CD40 (clone 3/23), IL-10 (intracellular; clone
JES5-16E3). The antibody specific for the CD21/CD35 complex
(clone 8D9) was purchased from eBioscience. As part of DC
characterisation by flow cytometry, the CD11c antibody (clone
HL3) was used.
Isolation of T- and B-cell populations
Freshly-isolated spleen and, where indicated, pancreatic lymph
nodes (PLN) were used. CD3+ T-cells were enriched from freshly-
collected spleen by passing splenocytes over columns (R&D
Systems). B-cells were enriched from the splenocytes by column-
assisted positive selection into CD19+ cells (Miltenyi Biotec). To
further enrich B-cells into those that produced IL-10, two methods
were pursued depending on the experiment. Method 1 involved a
first step enrichment of splenocytes from freshly-collected spleen
into IL-10-producing cells using the IL-10 Secretion Assay Cell
Enrichment & Detection Kit (Cat# 130-090-490, Miltenyi
Biotec). These cells were then further enriched into B220+
CD19+ cells by positive selection over specific selection columns.
In Method 2, IL-10 producing splenocytes were first isolated from
freshly-collected spleen using the selection kit referred to above.
These cells were then stained with fluorescence-tagged antibodies
and flow sorted into more homogeneous cell populations
depending on the experiment. All antibodies were purchased
from BD Biosciences.
IL-10-expressing CD1d+ CD5+ CD19+ regulatory B-cells
(‘‘B10 Bregs’’) were characterised and flow-sorted as described
[52,55]. Where B10 Bregs were used in functional studies in vitro,
they were first enriched into CD19+ B220+ cells using magnetic
isolation columns, followed by passage through the IL-10 pre-
enrichment column and then further flow-sorted into CD1d+
CD5+ cells.
Microscopy for B10 Bregs
Cytospins of flow-sorted B10 Bregs from freshly-collected
splenocytes of NOD female mice at 10 weeks of age were
processed for hematoxylin and eosin staining. Images were
captured by a Zeiss Axioplan2 microscope at 636magnification.
Ascertainment of suppressive B-cell frequency in vivo in
DC recipients
1–26106 cDC, iDC, or PBS vehicle were injected s.c. into mice
into the abdominal region overlying the predicted anatomical
location of the pancreas. Three days following DC injection,
spleens were harvested and processed into single cells. CD19+ B-
cell as well as B10 Breg frequency was measured by flow
cytometry. For some in vitro experiments (e.g. allogeneic mixed
leukocyte reactions (MLR)), cells from identically-treated mice
were flow sorted into B10 Bregs or B220+ CD19+ IL-10+
CD11c2 B-cells from IL-10-producing, pre-enriched B-cells prior
to co-culture or further characterisation.
Proliferation of IL-10-expressing B-cells and conversion of
B-cells into IL-10-expressing cells in vitro
B-cells were enriched from splenocytes of IL10gfp transgenic
mice; splenocytes from these transgenic mice were first enriched
into CD19+ B220+ CD11c2 GFP-negative or CD19+ B220+
CD11c2 GFP-positive cells by sequential selection over commer-
cially-available magnetic columns (Miltenyi Biotec) and then flow
sorted to purity into GFP+ or GFP2 cells. For flow cytometry and
flow sorting, stringent control for B-cell autofluorescence was
conducted by establishing the cell selection gate using B-cells from
the wild-type strain of the transgenic as well as very stringent
gating to remove autofluorescent cells co-incident inside the GFP+
cell populations. All cells whose fluorescence in the GFP channel
overlapped with that of the non-transgenic B-cells were considered
GFP2 cells. The GFP2 and GFP+ cells were seeded in triplicate
at 56104–16105 cells in the presence of an equal number of cDC
or iDC, or in medium alone. Five days later, the frequency of
GFP+ and GFP2 cells was ascertained by flow cytometry.
Proliferation of T-cells in vitro
Freshly-isolated splenocytes were irradiated (2800 rad) in
preparation for MLR co-cultures. Cells were plated as phenotyp-
ically-homogeneous populations (splenocytes alone, T-cells alone,
B-cells alone) or in co-culture with the following cell numbers per
well: Splenocytes at 26105 cells, T-cells at 26105 cells, and B-cells
at 26104–26105 cells. IL-10 neutralising antibody at a 1 micro-
gram/ml final concentration (eBiosciences) was added to some co-
cultures to determine the role of IL-10 in suppression. On day 4
post-plating, BrdU was added to individual wells to a final
concentration of 1 mM. T-cell proliferation was measured with
the FITC BrdU Flow Kit (BD Biosciences) on day 5 by flow
cytometry.
To determine if soluble mediators were involved in B-cell-
induced suppression, allogeneic MLR co-cultures with splenic or
Suppressive B-Cells, DC and Type 1 Diabetes
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PLN cells were re-established in HTS Transwell – 96 Well
Permeable Plates with a membrane pore size of 0.4 micrometers
(Corning). Flow-sorted B-cells were added into the Transwell
system at a total of 1.256105 cells per well. B-cells were plated
onto the Transwell membrane, while T-cells and splenocytes
were co-cultured in the bottom chamber, below the insert.
Proliferation was ascertained by BrdU incorporation using flow
cytometry.
Gene expression
B10 Bregs and B220+ CD19+ IL-10+ CD11c2 B-cells were
flow-sorted from freshly-isolated splenocytes to .95% purity.
Total mRNA was obtained using the MACS mRNA Isolation
System (Miltenyi Biotec) in preparation for RT-PCR. cDNA was
synthesised using the SuperScript III System (Invitrogen) and
then real-time PCR to amplify retinoic acid receptor (RAR) alpha
and retinoid X receptor (RXR) cDNA was conducted with the iQ
SYBR Green Mix (BioRad) in an iCycler. Relative steady-state
mRNA levels were calculated based on the 2D-DCt method after
correction for GAPDH housekeeping gene expression levels.
Primer sequences used (adopted from [64])
RAR alpha: forward: 59-AGGCCATCACAACTACCTGC-39
reverse: 59-GGAAAGAAGAAGGCGTAGGG-39
RXR:
forward: 59-CTTTGACAGGGTGCTAACAGAGC-39
reverse: 59-ACGCTTCTAGTGACGCATACACC-39
GAPDH (housekeeping control):
forward: 59-GGGTGGAGCCAAACGGGTC-39
reverse: 59-GGAGTTGCTGTTGAAGTCGC-39
Ascertainment of RA production by DC in vitro and flow sorting of RA-
producing cells.
Complementary methods were used to detect and confirm
RA production by DC. In the first, we used the ALDEFLUOR
reagent (StemCell Technologies), a substrate of ALDH [65,66]
to flow sort RA-producing CD11c+ cells. In some instances,
cells were co-stained with antibodies for specific cell surface
proteins in order to measure specific populations by flow
cytometry or to flow sort along RA positivity. To confirm RA
production, we co-cultured candidate DC populations with
HEK293 cells transiently-transfected with a luciferase reporter
under the control of a minimal promoter with multiple RA
response elements (SABiosciences), where the DC and the
transfected cells were separated by Transwell. The DC were
placed on the upper chamber membrane while the transfected
reported cells were placed in the lower plate wells. DC were
co-cultured with the reporter cells for 24–72 hours and the
level of luciferase activity (Dual Luciferase Assay; Promega)
was used as an indirect measure of bioactive RA production by
DC. Appropriate controls included untransfected cells, report-
er cells alone, medium alone and DC only. Additionally, we
also conducted the experiments using dual-reporter HEK293
cells where two plasmids were co-transfected (Renilla-Luc as
the transfection control and firefly-Luc under the control of the
RA respnse element minimal promoter).
Statistical considerations
Statistically-relevant differences among means (Student’s t-test,
ANOVA) or medians (Kruskal-Wallis test) were ascertained using
GraphPad Prism version 4 software (GraphPad). In all statistical
analyses, a p value,0.05 was considered to represent statistically-
significant differences.
Results
Antisense oligonucleotide-treated, co-stimulation-
impaired, immunoregulatory DC (iDC) reverse new-onset
hyperglycemia in NOD mice
We compared the efficacy of iDC and cDC to stably restore
non-fasting blood glucose to pre-diabetic levels in NOD female
mice. In Figure 1a we show that, even though a single iDC
injection can transiently reverse new-onset T1D (return to diabetes
as early as one week after insulin withdrawal), multiple injections
are required for stable, long-term restoration of blood glucose to
levels that reflect pre-diabetic conditions (non-fasting glucose levels
were, on average, 218+/263 mg/dL when combining all time
points measured; n= 9 NOD mice at 22 weeks). A single cDC
injection was ineffective at maintaining non-fasting blood glucose
below 280 mg/dL past 12–16 days following the injection (data
not shown). Stable restoration of non-fasting glucose levels, in the
absence of any exogenous insulin administration, was maintained
in all but three iDC recipients for at least 4 months after cessation
of iDC administration. Interestingly, multiple cDC injections also
exhibited some capacity for T1D reversal (2/10 mice; 20%),
although only one of the two reversed mice returned to
hyperglycemia by four months after the last cDC injection.
Figure 1b shows that blood glucose crosses the 280 mg/dL
threshold following insulin withdrawal in new-onset diabetic NOD
mice (n = 5) left untreated. Thus, residual insulin from previous
administration alone cannot account for the effects of cDC or iDC
in stably-restored blood glucose levels in the mice represented in
Figure 1a. Furthermore, the mean non-fasting glucose levels at
each time point shown in Figure 1a in our iDC-treated cohorts
were comparable to those observed in another DC-based reversal
approach [67].
iDC administration into NOD mice induces an increase in
the frequency of suppressive CD19+ B220+ CD11c2 IL-
10+ cells
Our findings in humans suggested that iDC increase the
frequency of suppressive B-cells [57]. Since then, we have shown
that exposure of human B-cells to iDC in culture results in
proliferation of existing Bregs [61]. We therefore hypothesised
that, in addition to the involvement of CD4+ CD25+ T-cells [23],
part of the beneficial results of iDC-induced reversal of T1D in
NOD mice could involve an iDC-induced expansion of suppres-
sive B-cells, including CD1d+ CD5+ Bregs. To address this
hypothesis, non-diabetic female NOD mice (8–18 weeks of age)
were given a single injection of cDC or iDC. When mice were
administered cDC, we observed a slight increase in IL-10+ cells
inside a population of CD19+ B220+ CD11c2 cells in spleen
(Figure 2a), although compared to untreated control recipients,
this difference was not statistically-relevant. In contrast, iDC
recipients exhibited a substantial and statistically-significant
increase in the frequency and number of these B-cells (Figure 2a
and summarised in the graphs in Figure 2c). CD1d+ CD5+ cells
inside the population of IL-10+ cells also increased slightly in
frequency in cDC recipients although at a statistically-insignificant
level, but the increase in iDC recipients was remarkable and
statistically-relevant when compared to cDC and control-treated
recipients. The same effect was observed when single cells from
pancreatic lymph nodes were examined (Figure 2b) Figures 2c–2f
summarise the differences in the frequency and actual numbers of
splenic CD19+ B220+ CD11c2 IL-10+ B-cells as well as B10
Bregs in untreated, cDC and iDC-administered NOD mice. B10
Bregs have never been observed microscopically. For the first time,
Suppressive B-Cells, DC and Type 1 Diabetes
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we show these cells under high-power magnification in Figure 2g.
These cells were flow-sorted to purity from freshly-collected
splenocytes of a 10 week old NOD female mouse. Their
morphology was consistent when sorted from five different age-
matched females. Even though these B-cells are detectable by flow
cytometry in cells from pancreatic lymph nodes (PLN), they are
very low in numbers. This limitation, along with the concern that
pooling of PLN-cells from multiple mice could yield confounding
data, impeded our desire to identify absolute cell number
differences in PLN of cDC/iDC/untreated mice.
To ascertain if the DC-responsive, splenic CD19+ B220+
CD11c2 IL-10+ B-cells represented, or contained Breg popula-
tions, we performed an allogeneic MLR assay. Freshly-collected
splenocytes from iDC-injected NOD female mice, first enriched
into IL-10-producing cells and then flow sorted into a CD19+
B220+ CD11c2 population, were added at a 1:10 and 1:1 ratio to
syngeneic splenic T-cells and allogeneic irradiated splenocytes. In
Figure 3a we show that at a B-cell:T-cell ratio of 1:10, the CD19+
B220+ CD11c2 IL-10+ B-cells isolated from both the cDC and
iDC-treated NOD mice were sufficient to significantly reduce T-
cell proliferation by at least 50%. At the higher 1:1 ratio, this B-cell
population isolated from both cDC and iDC NOD recipients
significantly reduced T-cell proliferation by <67% (Figure 3a).
The addition of an IL-10 neutralising antibody was unable to
prevent the suppression of T-cell proliferation in the presence of
these B-cells (Figure 3b). Furthermore, the physical separation of
these B-cells from the allogeneic MLR co-culture by Transwell
barrier resulted in the loss of suppression of T-cell proliferation
(Figure 3c). These data suggest that CD19+ B220+ CD11c2 IL-
10+ B-cells represent a population of suppressive B-cells where IL-
10, even if produced, may not be required for their suppressive
ability, at least in vitro. We tentatively assign the term ‘‘DC-Bregs’’
to this B-cell population, given their response to iDC.
cDC and iDC induce proliferation of DC-Bregs and
convert B-cells into IL-10-expressing DC-Bregs in vitro
To determine if the increase in DC-Bregs in DC recipients is a
result of a DC-induced proliferative signal to existing DC-Bregs or
a consequence of differentation of CD19+ B-cells into IL-10-
producing cells, we co-cultured CD19+ B220+ CD11c2 B-cells
flow sorted from freshly-isolated spleen of transgenic mice
expressing the GFP reporter from the IL-10 promoter (IL10gfp
mice) with cDC or iDC generated from the wild-type, non-
transgenic, C57BL/6 strain. At the same time, to determine if DC
caused CD19+ B220+ CD11c2 B-cells to acquire GFP (IL-10)
expression (i.e. a differentiation/conversion mechanism) we co-
cultured flow-sorted CD19+ B220+ CD11c2 GFP-negative cells
with the cDC, iDC or alone. In all instances, the sorted cells were
.80% viable at the onset of culture (top most histogram,
Figure 4a). The GFP+ sorted cells were routinely .95% pure
(top most histogram, Figure 4a) upon culture initiation. After 5
days in culture, we measured the frequency of GFP+ cells by flow
cytometry (representative experimental outcome shown Figure 4a).
Figures 4b and 4c summarise the outcome of these co-culture
experiments on an absolute cell number basis and show that cDC
and iDC induced an increase in GFP+ cell number when the
Figure 1. Stable reversal of T1D in NOD mice is achieved by multiple iDC injections. a. Multiple iDC injections (n = 8, blue lines) stably
maintain glucose levels within a range between 100–280 mg/dL in most new-onset T1D NOD mice. Multiple control DC injections (n = 8, green lines)
reversed T1D in a few recipients, albeit transiently. Single iDC injections (black lines), compared to multiple injections were ineffective in restoration
of blood glucose stability. The lines represent non-fasting blood glucose levels in individual NOD mice. Mice were first administered insulin once
diabetic hyperglycemia was confirmed until the time glucose levels dropped to below 280 mg/dL (5–8 days on average). At this point, insulin was
withdrawn. Then, 26106 DC (cDC or iDC) were injected s.c at the abdominal flank overlying the gastrointestinal organs. Time 0 represents the time of
diabetes confirmation. The black arrow below the x-axis shows the time of insulin withdrawal concomitant with the first DC injection. The coloured
arrows show the times at which DC were administered (single or multiple). The dashed lines in the graph indicate the minimum and maximum non-
fasting blood glucose levels measured in the reversed iDC treatment group. b. Blood glucose crosses the 280 mg/dL threshold within a day of insulin
withdrawal when new-onset diabetic NOD mice (n = 5) are not subjected to any other treatment. These data indicate that insulin administration alone
cannot account for the effects of cDC or iDC in prolonging normoglycemia in NOD mouse cohorts shown in Figure 1a.
doi:10.1371/journal.pone.0083575.g001
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sorted input B-cells were GFP+ (Figures 4b and 4c) reflecting
proliferation in vitro. cDC and iDC also induced an increase in the
GFP+ cell number when the input B-cells were GFP2 (Figures 4d
and 4e), reflecting a concomitant conversion mechanism. Viability
of cells at the end of the 5 days was no less than 80% (data not
shown). When comparing the actual number of GFP+ cells in the
co-cultures at the end of the experiments, it becomes evident that
both proliferation and differentiation events co-incide in the
presence of cDC and iDC, with the effects of iDC greater in
magnitude than cDC (Figure 4b compared to Figure 4c).
Figure 2. iDC administration into NODmice promotes an increase in the frequency of CD19+ B220+ CD11c2 IL-10+ B-cells as well as
B10 Bregs in vivo. 26106 cDC or iDC were injected into NOD female mice (8–10 weeks) s.c. into the abdominal flank overlying the gastrointestinal
organs. Three days later, the spleens were collected and the frequency of the CD19+ B220+ CD11c2 IL-10+ B-cells as well as B10 Bregs was measured
by flow cytometry. Absolute numbers were calculated based on hematocrit measurements of total viable single cells recovered from the tissue. a.
Shown is the flow cytometric approach used to identify and measure the frequency of the CD19+ B220+ CD11c2 IL-10+ cells (DC-Bregs; top two
histograms) and B10 Bregs (bottom two histograms). The results shown are representative of analyses conducted in freshly-collected splenocytes of
at least four different NOD recipients of each type of DC population (and PBS vehicle control). b. The data are representative of analyses conducted in
freshly-collected pancreatic lymph node single cells acquired from the same mice (n = 4 per treatment type) referred to above in (a). c. The graph
summarises the frequency of CD19+ B220+ CD11c2 IL-10+ B-cells (DC-Bregs) measured by flow cytometry as a % of total splenocytes. The number of
mice from which tissue was collected per treatment type is shown at the top of the bars which represent the median value. The error bars reflect the
SD. The differences between iDC and cDC/control untreated were statistically-significant (p,0.005, Kruskal-Wallis test of variance). d. The graph
summarises the absolute number of DC-Bregs measured by flow cytometry in the freshly-collected spleens of the untreated, cDC and iDC-injected
NOD mice (same mice as in [c] above). The bars represent the medians and the error bars the SD. The differences among the medians was
statistically-significant as shown in the graph (Kruskal-Wallis test of variance). e. The graph summarises the frequency of B10 Bregs (CD19+ CD1d+
CD5+ Il-10+ cells) measured by flow cytometry as a % of total splenocytes. The number of mice from which tissue was collected per treatment type is
shown at the top of the bars which represent the median value. The error bars reflect the SD. The differences between iDC and cDC/control untreated
were statistically-significant (p,0.05, Kruskal-Wallis test of variance). f. The graph summarises the absolute number of B10 Bregs measured by flow
cytometry in the freshly-collected spleens of the untreated, cDC and iDC-injected NOD mice (same mice as in [e] above). The bars represent the
medians and the error bars the SD. The differences among the medians was statistically-significant (p,0.005, Kruskal-Wallis test of variance). g.
Hematoxylin/Eosin-stained cytospin of flow-sorted B10 Bregs. Cells were sorted from freshly-isolated splenocytes of a 10 week-old female non-
diabetic NOD mouse. Magnification663. The morphology is identical among cytospins from another 5 age-matched female NOD mice.
doi:10.1371/journal.pone.0083575.g002
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Figure 3. CD19+ B220+ CD11c2 IL-10+ B-cells (DC-Bregs) are functionally-suppressive in allogeneic MLR in vitro and do not require
IL-10 to mediate suppression. a. Quintuplicate wells of splenic T-cells, irradiated splenocytes (alone, together, or in the presence of CD19+ B220+
CD11c2 IL-10+ B-cells) were incubated for 5 days. On the last day, BrdU was added. The number of BrdU+ cells was measured by flow cytometry on
day 6. Cultures consisted of 16105 T-cells from the spleen of NOD female mice (8 weeks), irradiated allogeneic splenocytes (C57BL/6 males, 8 weeks)
and purified CD19+ B220+ CD11c2 IL-10+ B-cells (combination of column enrichment and flow sorting as described in the Methods). Proliferation of
only T-cells or splenocytes was taken to represent 100% proliferation in these analyses. The bars represent the mean of n = 5 wells and the error bars
represent the SEM. The differences in proliferation in co-cultures of CD19+ B220+ CD11c2 IL-10+ B-cells in the absence of cDC or iDC compared to
those in the presence of the DC are statistically-significant (p values shown in graph on top of bars as single, double (p,0.05, ANOVA) or triple
asterisks (p,0.01, ANOVA). The last two sets of bars compare the proliferation fo the T-cells at a 1:10 and a 1:1 ratio of DC-Breg: T-cell numbers. b.
CD19+ B220+ CD11c2 IL-10+ B-cells (DC-Bregs) are suppressive in allogeneic MLR even in the presence of a neutralising IL-10 antibody but not when
physically separated from the T-cells/antigen-presenting cells. Quintuplicate wells of splenic T-cells, irradiated splenocytes (alone, together, or in the
presence of DC-Bregs) were incubated for 5 days. The ratio of DC-Breg:T-cell numbers was 1:10 in all co-cultures. On the last day, BrdU was added.
Anti-IL-10 antibody was added at 1 microgram/mL where shown. Proliferation of T-cells in the presence of irradiated splenocytes was taken to
represent 100% proliferation. The bars represent the means of BrdU+ cells as a % of BrdU+ in the control T-cells:splenocyte co-cultures (n = 5 wells)
and the error bars represent the SEM. The differences in T-cell proliferation in co-cultures in the absence of DC-Bregs and those in the presence of DC
are statistically-significant (p values shown in graph, ANOVA). c. DC-Bregs cannot suppress the proliferation of Transwell barrier-sequestered T-cells in
allogeneic MLR in vitro. MLR was conducted with DC-Bregs added on top of a Transwell insert separating co-cultures of T-cells and allogeneic
irradiated splenocytes. The ratio of DC-Breg:T-cell numbers was 1:10 in all co-cultures Anti-IL-10 antibody was added at 1 microgram/mL where
shown on top of the Transwell insert (with the DC-Bregs). Proliferation of cells in the bottom of the dish (T-cells:splenocyte co-cultures) in the absence
of DC-Bregs was taken to represent 100% proliferation in these analyses. N = 5 wells for each co-culture shown. N.S. = differences among means were
not significant (p.0.05).
doi:10.1371/journal.pone.0083575.g003
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B10 Bregs are the majority B-cell constituent of the
suppressive DC-Bregs
CD19 and B220 co-positivity reflects a heterogeneous leukocyte
population enriched in B-cells, thus, DC-Bregs are expected to
represent a wide array of B-cells at different stages of differenti-
ation and of variable function. We considered it highly-unlikely
that every single cell in this population was inherently suppressive.
In order to identify the suppressive constituent population(s) and to
determine if cDC/iDC affected these populations specifically, in
the same manner as they affected the heterogeneous DC-Breg
cells, we first phenotypically-characterised the DC-Bregs. We first
focused on cell surface markers associated with recently-reported
Figure 4. cDC and iDC promote proliferation of DC-Bregs as well as conversion of IL-102 into IL-10+ DC-Bregs in vitro. a. Freshly-
collected splenocytes from IL10gfp transgenic mice were flow sorted into CD19+ B220+ CD11c2 GFP+ or CD19+ B220+ CD11c2 GFP2 populations
with very stringent gating to exclude autofluorescent cells based on the fluorescence characteristics of flow-sorted CD19+ B220+ CD11c2 cells from
freshly-collected splenocytes of the wild-type mouse strain (far right panel inset). Purity of the GFP+ after sorting (indicated as IL-10 versus FSC in the
top most quadrant plot) as well as cell viability (Live/Dead staining in the histogram adjacent to the top most quadrant plot), representative of all the
sorting outcomes performed in this experiment is shown. 56104 sorted cells (GFP+ or GFP2) were placed into co-culture with PBS, or an equal
number of cDC or iDC. Representative GFP fluorescence of the B-cells after 5 days in co-culture with cDC, iDC and media is shown in the histograms
with the GFP+ cells represented as a % of total cells in culture (values of this specific experiment, representative of three separately-conduced
experiments, are shown inside the histograms). b. The graph shows the actual number of GFP+ DC-Bregs in vitro after co-culture of a highly-purified
GFP2 starting population (56104 cells) with media, cDC or iDC. The bars indicate the mean of triplicate wells and the error bars the SEM. p,0.05
shown by asterisk (ANOVA). c. The graph shows the actual number of GFP+ DC-Bregs in vitro after co-culture of a highly-purified GFP+ starting
population (56104 cells) with media, cDC or iDC. The bars indicate the mean of triplicate wells and the error bars the SEM. p,0.05 shown by asterisk
(ANOVA).
doi:10.1371/journal.pone.0083575.g004
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mouse and human Bregs as well as other cell surface markers that
could give an insight into their ontogeny and their mechanisms of
action. Figure 5 shows the outcome of a representative flow
cytometric characterisation of NOD DC-Bregs enriched into
CD19+ B220+ CD11c2 cells from freshly-collected splenocytes.
Although we did not exhaustively determine the expression of all
possible B-cell markers, the NOD DC-Bregs expressed surface IgD
and IgM, CD10, CD21, CD27 and CD38. Interestingly, the DC-
Bregs also expressed CD40. Based on the marker presence and the
mean fluorescence intensity, we tentatively consider DC-Bregs to
be CD19+ B220+ CD11c2, IgDHIGH, IgM+, CD10LOW, CD21+,
CD27+, CD38+, CD40HIGH, IL-10+, suggesting the possible
presence of at least one memory B-cell population (based on the
presence of CD19+ CD27+ CD38+ CD40+; [68,69]). This
memory subpopulation may be resting/proliferating and may or
may not represent suppressive cells. These are questions that we
are currently addressing.
At the same time, it was apparent that the DC-Bregs also
exhibited features reminiscent of B10 Bregs [55]. We thus sought
to determine if B10 Bregs were the sole, or at least one of the
suppressive populations comprising the DC-Bregs. Using the
IL10gfp transgenic strain as a source of B-cells we discovered that
B10 Breg-depleted DC-Bregs (i.e. the cells that remain in the
effluent as IL-102 CD1d2 CD52 CD19+ B220+ CD11c2 cells
during flow sorting of freshly-collected splenocytes into B10 Bregs)
Figure 5. Flow cytometric characterisation of splenic DC-Bregs from NOD mice. Gating was established as shown (CD19+ B220+ CD11c2).
The frequency of cells expressing each of the surface proteins indicated in the histograms inside this gate further established the phenotype of the
DC-Bregs in freshly-isolated spleen of NOD female mice (10 weeks of age). The data shown are representative of the flow cytometric anlyses of
freshly-acquired splenocytes from three different age-matched NOD mice. Surface markers include IgD, IgM, CD10, CD21, CD27, CD38 and CD40.
doi:10.1371/journal.pone.0083575.g005
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exhibit a trend of suppressive ability, however, on a statistical basis
there were no differences among co-cultures (Figure 6).
B10 Bregs express RA receptors
Given the data demonstrating that B10 Bregs account for most
of the suppressive activity in the DC-Breg population, we decided
to focus on the B10 Bregs from this point onward. Indirect
observations suggest that B-cells accumulating into inflamed
intestinal tissue share features with Bregs [70]. RA appears to be
one of the molecules that direct such homing [70]. RA is also
central in the differentiation of T-cells into Foxp3+ Tregs [71].
Furthermore, we have recently demonstrated the highly-purified
human CD19+ CD24+ CD38+ Bregs express RA receptor alpha
and are response to RA in vitro [72]. To determine if B10 Bregs are
formally able to respond to RA, we performed real-time, semi-
quantitative RT-PCR on IL10gfp-derived flow sorted B10 Bregs
for RA receptor (RAR) isoforms. In Figure 7 we show that B10
Bregs as well as DC-Bregs (represented as CD11c2 IL-10+ in the
graphs) express RAR and the retinoid X receptor (RXR).
Diabetes-suppressive DC produce RA
Affymetrix expression technology showed that human cDC and
iDC as well as cDC and iDC generated from NOD mouse bone
marrow progenitors express aldhehyde dehydorgenases 1 and 2
(ALDH), rate-limiting enzymes for RA biosynthesis [65,66,72].
iDC in particular expressed significantly greater steady-state
amounts of the 1A2 isoform associated with tolerogenic DC [73]
compared to cDC (data not shown). In Figure 8a we demonstrate
that cDC and iDC produce RA. ALDEFLUOR conversion to
fluorescent product indicates that ALDH is enzymatically-active in
these cells. The frequency of ALDH+ DC as a percentage of gated
cells in cDC and iDC is similar. However, on a per cell basis
(reflected in the geometric mean fluorescence intensity; Figure 8a),
iDC are twice as reactive with the ALDEFLUOR reagent
compared to cDC. This may reflect more ALDH enzyme levels
per cell, a faster catalytic rate for RA biosynthesis or both. In
Figure 8b we confirm that cDC and iDC produce bioactive RA.
By 24 hours, however, the concentration of bioactive RA
produced by both cDC and iDC was at levels able to comparably
stimulate RA-dependent reporter gene activity in vitro (Figure 8c).
Figure 6. B10 Breg-depleted DC-Bregs are not suppressive in allogeneic MLR in vitro. The graph shows the frequency of BrdU-positive
(proliferating) T-cells from freshly-isolated spleen of IL10gfp transgenic mice in the presence or absence of syngeneic CD1d, CD5, IL-10-depleted B-
cells (represented in the graph as ‘‘IL-102 CD1d2 CD52 B-cells’’) and allogeneic, irradiated splenocytes (Spl). The B-cells (DC-Bregs or B10 Breg-
depleted DC-Bregs) were added at a 1:1 or a 1:10 ratio of B-cells:T-cells. The frequency of BrdU+ cells was measured by flow cytometry and the data
are shown as BrdU+ cells as a % of control, where control refers to the frequency of proliferation of T-cells in the presence of only irradiated
allogeneic splenocytes (taken to be 100%). The bars represent the mean and the error bars the SEM (triplicate culture dish wells). The differences in
proliferation of T-cells among the co-cultures were not statistically-significant (p = 0.118, ANOVA) The data are representative of two independently-
conducted experiments.
doi:10.1371/journal.pone.0083575.g006
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Discussion
Despite convincing arguments supporting the consideration to
use tolerogenic DC in human disease and/or transplantation [26]
no attempt had been made until 2007. Our group was the first to
test the safety of autologous co-stimulation-impaired DC in
established T1D patients. The outcome was reported in 2011
[57]. Those DC are essentially identical to the ones described
herein. Both the human and the murine DC are generated in the
presence of a mixture of phosphorothioate DNA oligonucleotides
targeting the primary transcripts of CD40, CD80 and CD86. One
novel and intriguing outcome of the clinical trial was the increased
frequency of B-cells presenting an immunosuppressive character in
vitro, particularly in iDC recipients. This prompted us to
investigate a mechanistic link between our tolerogenic DC and
immunosuppressive B-cells. We have recently shown that human
iDC induce the differentiation of human B-cells into suppressive
B-cells in vitro [61] establishing for the very first time a link between
tolerogenic DC and suppressive B-cells, potentially Bregs.
Although production of IL-10 appears to be characteristic of all
Bregs identified to date, the surface phenotype of the different
populations described is very variable. Some studies have
identified suppressive acitivty in CD5+ B1a cells, CD21+
CD232 marginal zone cells, or CD1d+ CD21+ CD23+ T2-
marginal zone precursor B-cells [74]. In humans, the suppressive
activity seems to concentrate inside CD19+ CD24+ CD27+
CD38+ cells [30,56]. Production of IL-10 however is not
necessarily a condition for B-cells, including Bregs, to confer
suppression - at least in vitro - and not all IL-10-producing B-cells
are necessarily regulatory [75]. Accumulating evidence suggests a
model where IL-10 expression may be transient as B-cells with
suppressive potential could transition through an IL-10-expressing
phase. These cells come to rest as immunoglobulin-secreting cells
with suppressive capacity, although they are not solely, or
completely reliant on IL-10 for suppressive capacity [76]. Based
on these observations, models have been proposed where Bregs,
including the B10 population, emerge from a transitional and/or
memory population consequent to antigen exposure and BCR
activation. The same models predict that the Breg BCR repertoire
is polyclonal.
Based on such observations, we propose that B-cells, in general,
have an intrinsic potential to differentiate or to transition through
states where they can suppress the proliferation of other B-cells as
well as T-cells, but that this potential is only realised and activated
in response to microenvironmental signals including those from
tolerogenic DC. Given the requirement to provide CD40
stimulation for Bregs to expand [52,76,77,78], one potential signal
concurrent with BCR activation could be CD40 Ligand. BCR-
Figure 7. DC-Bregs and B10 Bregs express RA receptors. Real-time, semi-quantitative RT-PCR confirms the presence of steady-state mRNA of
RA receptor alpha (Figure 7a) as well as low levels of retinoid X receptor (Figure 7b) in highly-purified (flow-sorted) DC-Bregs and B10 Bregs from
freshly-isolated spleen of IL10gfp transgenic mice. The gel images in Figure 7a and 7b show the RT-PCR products from flow-sorted B10 Bregs. The
steady-state mRNA levels of RARalpha and RXR from the B10 Bregs were used as the controls and the values were taken to represent 100% receptor
expression. Steady-state mRNA levels of RARalpha and RXR in non-B10 Breg populations are shown in the graphs underneath the gel images
normalised to the B10 Breg value and presented as fold under or overexpression. Steady-state RARalpha mRNA was detected in B10 Bregs (first bar in
graph; leftmost)), IL-102 CD19+ CD5+ CD1d+ cells (second bar in graph), DC-Bregs (third bar in graph), and IL-102 DC-Bregs (last bar in graph;
rightmost). The bars represent the medians and the error bars the SD. These data are representative of steady-state mRNA from flow sorted cells from
two different spleens of age-matched mice (10 week-old females).
doi:10.1371/journal.pone.0083575.g007
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activated B-cells produce IL-10 and their adoptive transfer into
NOD mice reduced disease incidence and severity [79]. CD40
Ligand is expressed on TLR9-activated myeloid DC [80], as well
as on activated CD4+ T-cells [81,82] which operate through B:T-
cell interactions [83,84,85]. When considering the interplay
among DC:T-cells:B-cells in the context of CD40 Ligand and
microenvironmental influences through cytokines, including IL-
21, recently shown to induce significant expansion of B10 Bregs
[86], one could appreciate why the suppressive potential of B-cells,
even though described more than three decades ago [87,88],
eluded many investigators.
Modulation of B-cell frequency as an approach to attenuate
autoimmunity is not a new concept. Many studies have shown that
B-cell depletion ameliorates, prevents and in some instances can
reverse autoimmunity [45,89,90,91,92,93,94,95]. Mechanistic
insights indicate anergy and immune deviation along with an
increased threshold for antigen presentation as operationally-
underlying the disease prevention and improvement
[45,89,90,91,92,93,94,95]. Accumulating data, however, strongly
suggest that B-cell depletion is followed by a period of homeostatic
expansion of B-1 type, transitional B-lymphocytes, and their
progenitors [96,97,98,99] and the surface phenotypes of those cells
are strongly suggestive of B-cells with a regulatory, immunosup-
pressive ability [97,98], although this has not been formally
demonstrated. Indeed, such a mechanism, involving homeostatic
expansion of Bregs secondary to B-cell depletion could underlie
and partially explain the successful outcomes in islet allotrans-
plantation and reversal of T1D in NOD mice following B-cell
deletion using B-cell targeted antibodies [44,45,46,47].
The data shown in Figure 4 raise the question of why the
frequency of B-cells not expressing GFP from the IL-10 promoter
was considerably lower, in contrast to the higher frequency of
GFP-expressing cells when co-cultured in the presence of cDC/
iDC (iDC effects.cDC; Figure 4). One possible interpretation is
that immature DC (cDC) and tolerogenic DC confer increased
survival (i.e. increased anti-apoptotic states) selectively to suppres-
sive B-cells, and/or induce apoptosis selectively in non-suppressive
B-cells. These two potential mechanisms need not be mutually-
exlusive. Since B10 Bregs produce IL-10, and their frequency is
increased in response to tolerogenic DC, this IL-10 could act in an
autocrine manner as well as in a paracrine fashion to bolster
regulatory cell networks that rely on IL-10 for their function. IL-10
is a well-known survival factor for many cell types including B-cells
(depending on their state of activation; [100,101]). We speculate
that there are differences in IL-10 receptor levels and possibly
signaling among B10 Bregs, DC-Bregs and non-suppressive B-
cells. Furthermore, we also speculate that receptors for possibly
other pro-survival signals are preferentially-expressed on the cell
surface of suppressive B-cells compared to non-suppressive cells.
We are currently studying these possible mechanisms.
Our recent findings in human cells showing a potential role for
RA in suppressive B-cell biology [72] are now also relevant at least
for mouse B10 Bregs. RA, a molecule relevant in tolerance
mechanisms, could be one of a number of soluble factors that
condition or confer fitness to B-cells to assume and to stabilise a
suppressive ability. RA-producing DC are immunosuppressive and
therapeutic in animal models of inflammatory bowel disease and
their efficacy rests on RA-mediated differentiation of Foxp3+
Figure 8. cDC and iDC produce bioactive RA in vitro. a. The ALDEFLUOR reagent stains aldehyde dehydrogenase-expressing cells and thus RA-
producing cells. Even though cDC are ALDEFLUOR+, and the frequency of CD11c+ ALDEFLUOR+ cDC is similar to CD11c+ ALDEFLUOR+ iDC (cDC:
8.7% cells are CD11c+ ALDEFLUOR+ compared to 9.5% of iDC), on a per-cell basis (Mean Fluorescence Intensity; MFI) iDC are twice as reactive with
ALDEFLUOR than cDC (44186 compared to 84374). The flow cytometric analysis shown is representative of duplicate cultures of four age- and sex-
matched NOD female mice (7 weeks of age). The two quadrant plots at the far left of the graph, in the inset, demonstrate the compensation
performed for the flow cytometry; there was no non-specific fluorescence (‘‘bleeding’’) into either of the measured channels. b. RA-response element
(RARE)-driven luciferase activity is detectable in RARE-Luc plasmid-transduced HEK293 cells cultured in the presence of cDC or iDC where DC were
placed on top of a Transwell barrier separating them from the RARE-Luc-transduced 293 cells. Luciferase activity was measured after 24 hours culture.
The bars represent the mean relative luminescence (arbitrary units) of triplicate cultures and the error bars represent the SEM. The differences
between the cDC and iDC means were not significant (Student’s t-test). HEK293 cells were co-transfected with a CMV-Renilla luciferase control
plasmid concurrently with the RARE-Luc (Firefly) to control for transfection efficiency. There were no differences in transfection efficiency as indicated
by statistically-indistinguishable Renilla activity among all cultures (not shown).
doi:10.1371/journal.pone.0083575.g008
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Tregs [57]. We now add suppressive B-cells/Bregs to the list. RA
production by iDC can explain, in part, our observations of
increased CD4+ CD25+ T-cell frequency in successfully-treated
NOD mice [23] as well as the increased frequency of suppressive
B-cells, which express, as we have shown herein, RA receptors.
The seminal findings of Clare-Salzer and colleagues [102], who
showed that B-cells were increased in frequency in NOD mice
injected DC from syngeneic pancreatic lymph nodes, could
represent an a process of DC-induced suppressive B-cell expan-
sion, as part of a therapeutic mechanism as they originally
reported.
Other groups who have studied Bregs to date, often prestimu-
late the cells with recombinant CD40L and/or PMA/ionomycin
[10]. We chose to avoid these in vitro manipulations primarily
because such treatments could potentialy alter the natural
phenotype and activity of freshly-acquired Bregs.
In summary, we have discovered that tolerogenic DC
engineered ex vivo for low co-stimulation ability increase
frequency and numbers of IL-10-expressing B-cells in vitro and
in vivo, consequent to concomitant proliferation of pre-existing IL-
10+ B-cells and conversion of CD19+ B-lymphcytes into IL-10-
expressing cells without affecting their immunosuppressive poten-
tial in vitro. We also discovered that these DC-sensitive putative
Bregs expressed receptors for retinoic acid which is produced by
the tolerogenic dendritic cells. Taken together, our findings usher
a potential new therapeutic approach to T1D immunotherapy
which involves suppresisve B-cells, possibly homogeneous Bregs,
together with approaches and molecules that stabilise their
suppressive ability and expand their numbers in vitro (e.g. RA,
IL-10, IL-21 [86]).
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